Moody Aldrich Partners’s Albany Molecular Research Inc AMRI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
Sell
-21,930
Closed -$308K 104
2017
Q1
$308K Sell
21,930
-43,117
-66% -$706K 0.53% 78
2016
Q4
$1.22M Sell
65,047
-74,730
-53% -$1.27M 0.79% 63
2016
Q3
$2.31M Buy
139,777
+14,520
+12% +$215K 1.61% 14
2016
Q2
$1.68M Buy
125,257
+78,752
+169% +$1.15M 1.39% 22
2016
Q1
$711K Buy
+46,505
New +$729K 1.5% 22

Other funds holding AMRI

Moody Aldrich Partners's AMRI Position: Q2 2017 in Review

Moody Aldrich Partners sold out of Albany Molecular Research Inc (AMRI) in Q2 2017, closing a stake of 21,930 shares — an estimated $308K sold.

Moody Aldrich Partners first reported a position in AMRI in Q1 2016 and held it in 5 quarters. The position peaked at $2.31M in Q3 2016. 136 funds tracked by Wall St. Rank hold AMRI as of Q2 2017.

  • Moody Aldrich Partners reported no remaining Albany Molecular Research Inc position as of Q2 2017 after selling out during the quarter.
  • Moody Aldrich Partners sold 21,930 Albany Molecular Research Inc shares in Q2 2017, an estimated $308K.
  • Moody Aldrich Partners first reported a position in Albany Molecular Research Inc in Q1 2016 and held it in 5 quarters.
  • Moody Aldrich Partners's Albany Molecular Research Inc position peaked at $2.31M in Q3 2016.
  • 136 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q2 2017.

Based on Moody Aldrich Partners's 13F filing for Q2 2017, filed 28 Jul 2017.